Does the ATTAIN-1 population resemble anyone asking about orforglipron here?

What I have: ATTAIN-1 · orforglipron.

I can parse the result. I am less sure what it licenses me to conclude.

I have deliberately not looked at anyone else’s interpretation yet.

Which parts of this are informative and which are decoration?

Check the ATTAIN-1 inclusion criteria against yourself in that order: entry BMI band, diabetes status, prior weight-loss attempts, and what the run-in excluded. Registration programmes recruit a population selected to show an effect if one exists, which is the right design and a poor basis for generalising. The run-in is the part that is easiest to miss: a programme that drops people during a placebo lead-in has already removed those least likely to tolerate or comply, and the published arms describe the survivors. External validity is not a property of the trial; it is a property of the distance between its population and yours, and that distance is yours to measure.

Start with what the trial was powered for. Everything else in the publication is secondary, exploratory, or a subgroup, and those three words mean three different things.

Duration decides what can be seen. A 68-week trial can measure weight and glycaemia; it cannot measure anything whose event rate is one per cent per year without enrolling tens of thousands.

In practice, a composite endpoint is only as informative as its least serious component. Where a cardiovascular composite combines death, infarction and stroke, ask which component moved, because they are not interchangeable outcomes.

The caveat is that trial evidence is about licensed product administered under supervision. None of it transfers automatically to research-grade material of unverified content.

When two sources disagree, the answer is almost always in the methods section of the one you have not read.

The short version: the effect is real, the magnitude depends on the population, and the population is usually the part that gets dropped when a result is quoted second-hand.

Confidence intervals matter more than point estimates when two trials disagree. Two studies reporting fifteen and twenty per cent whose intervals overlap heavily have not disagreed about anything.

The underlying point is that placebo arms in this class are not nothing. Lifestyle-intervention placebo arms in the major obesity trials commonly lose two to three per cent of body weight, so an active-arm figure quoted without its comparator overstates the drug effect by roughly that much.

The cardiovascular outcome programme in this class runs to several large randomised trials — LEADER for liraglutide, SUSTAIN-6 and SELECT for semaglutide, REWIND for dulaglutide — and they are the reason the class is discussed as more than a weight intervention.

One qualification: absence of a signal in a trial of this size is not evidence of absence for a rare event. It is evidence that the event is rarer than the trial could detect.

If a claim cannot be traced to a named trial with a named endpoint, treat it as a claim rather than as evidence.

The honest answer here is that the published evidence supports part of the claim and is silent on the rest, and it is worth being precise about which part is which.

Intention-to-treat and per-protocol analyses answer different questions. ITT asks what happens if you offer the treatment; per-protocol asks what happens if it is taken as directed. The gap between the two is a measure of how tolerable the protocol was.

Stated carefully, non-inferiority and superiority designs are not interchangeable. A non-inferiority result says the new agent is not meaningfully worse against a pre-specified margin — it does not say it is as good, and it certainly does not say it is better.

Where a result is quoted from a conference abstract rather than a peer-reviewed publication, the numbers routinely move between the two. It is worth checking which one you are reading.

Be careful about generalising from a trial population to yourself. The exclusion criteria are usually the most informative page in the supplement.

The short version: check the endpoint, check the comparator, check who was excluded, then look at the number.

edited 31 Jul 2024 by Dr_Tomas_Kral — added the placebo-arm figures

The relevant detail is that this is answerable from the published record, but only if you take the placebo arm seriously rather than reading the active arm alone.

Trial populations are selected. Exclusion criteria in this class routinely remove people with significant renal impairment, prior pancreatitis and unstable psychiatric illness, which is exactly the population the results are then quoted for.

I am not a clinician and this is not medical advice; it is a reading of a published protocol.

Quote the interval alongside the estimate and half the disagreements on this site would not start.